The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity and diabetes rates collide with expanding middle-class incomes,

India’s health regulator has approved Eli Lilly’s pre-filled pen version of Mounjaro, expanding its availability across six dosage strengths. The once-weekly injector, known as Mounjaro KwikPen, now covers doses ranging from 2.

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight management.